BAY3498264 clinical trials

A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation

This study is looking into a new drug, BAY3498264, given alongside sotorasib, for people with advanced solid cancers showing a specific genetic change called KRAS G12C. The main goal is to check how safe this combination is and find the right dose.